A woman holds a small bottle labeled with a “Coronavirus COVID-19 Vaccine” sticker and a medical syringe in front of displayed Pfizer logo in this illustration taken, October 30, 2020.

Dado Ruvic | Reuters

Pfizer said Tuesday it plans to file for full U.S. approval of its Covid-19 vaccine with German drugmaker BioNTech at the end of this month. If the FDA signs off, the company will be able to market the shot directly to consumers.

In releasing its first-quarter financial results, the company also reported $3.5 billion in first-quarter sales of its Covid-19 and reported earnings and revenue that beat Wall Street’s expectations.

Here’s how Pfizer did compared with what Wall Street expected, according to average estimates compiled by Refinitiv:

  • Adjusted EPS: 93 cents per share vs 77 cents expected
  • Revenue: $14.58 billion vs. $13.51 billion expected

The company now expects full-year sales of $26 billion from the vaccine, up from its previous forecast of about $15 billion.

Shares of Pfizer rose 1.4% after the news.

This is a developing story. Please check back for updates.



Source link

By admin

Leave a Reply

Your email address will not be published. Required fields are marked *